Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

By Yahoo! Finance | Oct 30, 2024 at 03:27 AM EST

Exelixis focuses on active molecules generating differentiating clinical data in the GU/GI space, agnostic to modality and deal size. The company leads in synthetic lethality assets with XL-309 and XL-495. Recent sales growth in cabo attributed to strong demand, particularly in RCC.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.